Northwest BiotherapeuticsNWBO
13F holders, Q4 2025 (December 31)7holders −2
0new positions
1sold out
$0.21avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, down 2 from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were VSM Wealth Advisory, LLC ($15K), Opus Capital Group, LLC ($14K) and Ethos Financial Group, LLC ($6K).
- Company
- Northwest Biotherapeutics
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $2K |
All 13F filers, Q3 2025 → Q4 2025: 18,000 shares bought and 10,000 shares sold, net +8,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| VSM Wealth Advisory, LLC | 0.00% | Add +22.9% | 80,574 | $15K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $14K |
| Ethos Financial Group, LLC | 0.00% | Add +11.8% | 28,350 | $6K |
| Williams Jones Wealth Management, LLC. | 0.00% | No change | 27,000 | $6K |
| Advisors Management Group Inc. | 0.00% | No change | 10,270 | $2K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | No change | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.